DLDominique Lombardo

Dominique Lombardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dominique Lombardo has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Françoise Silvy

    Aix Marseille Univ, INSERM, CRO2, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Marseille, France

    5 shared publications
  • Carole Siret

    3 shared publications
  • Emmanuelle Martinez

    Aix Marseille Univ, INSERM, CRO2, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Marseille, France

    3 shared publications
  • Eric Mas

    INSERM; Marseille, France; Aix-Marseille Univ; Centre de Recherche en Oncologie biologique et Oncopharmacologie; Marseille, France; Laboratoire d’Immunologie des Tumeurs; Institut Paoli-Calmettes; Marseille, France

    3 shared publications
  • Mehdi Ouaissi

    Aix-Marseille Université, CRO2, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Marseille, France

    3 shared publications
  • Anders Molven

    Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway

    2 shared publications

Latest Publications

  • Different effects of frameshift mutations occurring in the repeat region of the pancreatic enzyme carboxyl ester lipase (CEL)

    by Anny Gravdal, Ranveig Seim Brekke, Khadija El Jellas, Xunjun Xiao, Mark E. Lowe, Dominique Lombardo, Eric Mas, Bente Berg Johansson, Karianne Fjeld, Anders Molven

  • Open Access

    Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies?

    by Dominique Lombardo, Françoise Silvy, Isabelle Crenon, Emmanuelle Martinez, Aurélie Collignon, Evelyne Beraud, Eric Mas

    Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies? Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies?


  • Open Access

    Expression of truncated bile salt-dependent lipase variant in pancreatic pre-neoplastic lesions

    by Emmanuelle Martinez, Isabelle Crenon, Françoise Silvy, Jean Del Grande, Alice Mougel, Dolores Barea, Frederic Fina, Jean-Paul Bernard, Mehdi Ouaissi, Dominique Lombardo, et al.

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Emmanuelle Martinez1, 2, Isabelle Crenon1, 2, Françoise Silvy1, 2, Jean Del Grande3, Alice Mougel1, 2, Dolores Barea1, 2, Frederic Fina1, 2, 4, Jean-Paul Bernard1, 2, 5, Mehdi Ouaissi1, 2, 6, Dominique Lombardo1, 2, Eric Mas1, 2 1Aix-Marseille Université, CRO2, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Marseille, France 2INSERM, UMR_S 911, Marseille, France 3Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service d’Anatomopathologie, Marseille, France 4LBM- Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Service de transfert d’Oncologie Biologique, Marseille, France 5Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service de Gastroentérologie 2, Marseille, France 6Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service de Chirurgie Digestive et Viscérale, Marseille, France Correspondence to: Eric Mas, email: eric.mas@univ-amu.fr Dominique Lombardo, email: dominique.lombardo@univ-amu.fr Keywords: bile salt-dependent lipase, pancreatic cancer, antibodies Abbreviations: BSDL, bile salt-dependent lipase; PDAC, pancreatic adenocarcinoma Received: October 19, 2015 Accepted: August 13, 2016 Published: September 01, 2016


  • Sa1422 Saccharomyces boulardii CNCM I-745 Strengthen Intestinal Epithelial Barrier Through Action on E-Cadherin-Catenin Complex

    by Chloé Terciolo, Aurélie Dobric, Carole Siret, Mehdi Ouaissi, Françoise Silvy, Adel Hama, Sébastien Germain, Rénaté Bonier, Dominique Lombardo, Roisin Owens, et al.

  • Open Access

    Rs488087 single nucleotide polymorphism as predictive risk factor for pancreatic cancers

    by Emmanuelle Martinez, Françoise Silvy, Fréderic Fina, Marc Bartoli, Martin Krahn, Fabrice Barlesi, Dominique Figarella-Branger, Juan Iovanna, René Laugier, Mehdi Ouaissi, et al.

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Emmanuelle Martinez1, 2, Françoise Silvy1, 2, Fréderic Fina1, 2, 3, Marc Bartoli4, Martin Krahn4, 5, Fabrice Barlesi1, 2, 6, Dominique Figarella-Branger1, 2, 7, Juan Iovanna8, 9, 10, René Laugier11, Mehdi Ouaissi1, 2, 12, Dominique Lombardo1, 2, Eric Mas1, 2 1Aix-Marseille Université, CRO2, Centre de Recherche en Oncologie biologique et Oncopharmacologie, F-13005, Marseille, France 2INSERM, UMR_S 911, F-13005, Marseille, France 3LBM- Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Service de Transfert d’Oncologie Biologique, F-13015, Marseille, France 4Aix-Marseille Université, INSERM, UMR 910, F-13005, Marseille, France 5Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone-Enfants, Département de Génétique Médicale, F-13005, Marseille, France 6Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Service d’Oncologie Multidisciplinaire & Innovation Thérapeutique, F-13915, Marseille, France 7Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service d’Anatomopathologie, F-13005, Marseille, France 8Aix-Marseille Université, CRCM, Centre de Recherche en Cancérologie de Marseille, F-13009, Marseille, France 9INSERM, UMR_S 1068, F-13009, Marseille, France 10CNRS, UMR 7258, F-13009, Marseille, France 11Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service de Gastroentérologie, F-13005, Marseille, France 12Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service de Chirurgie Digestive et Viscérale, F-13005, Marseille, France Correspondence to: Eric Mas, e-mail: eric.mas@univ-amu.fr Dominique Lombardo, e-mail: dominique.lombardo@univ-amu.fr Keywords: SNP, rs488087, pancreatic cancer Abbreviations: BSDL, bile-salt-dependent lipase; PDAC, pancreatic ductal adenocarcinoma; PC, pancreatic cancers Received: June 23, 2015 Accepted: October 05, 2015 Published: October 16, 2015


  • Carboxyl-ester lipase (CEL) as biomarker in pancreas cancer: Characterization of the monoclonal antibody 16D10 targeting pancreatic neoplastic cells and cross-reacting with histo-blood group A antigens

    by Khadija El Jellas, Heike Immervoll, Ole Steffensen, Bente Berg Johansson, Karianne Fjeld, Dominique Lombardo, Pĺl Rasmus Njřlstad, Eric Mas, Anders Molven


  • Open Access

    Exosomal lipids impact on tumoral cell behavior

    by Dominique Lombardo, Carole Siret, Sadia Beloribi-Djefaflia

    The transfer of proteins or genetic material from exosomes and the subsequent effects on cell fate are well described.1 However lipids effects on cell behavior remain less documented.2 Few years ag...


  • Open Access

    Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR-4SDF-1α signaling axis

    by Sadia Beloribi-Djefaflia, Carole Siret, Dominique Lombardo

    We previously reported that exosomes secreted by human pancreatic tumor cells induce cell death through the inhibition of the Notch-1 survival pathway (Ristorcelli et al., 2009). We demonstrated that exosomal lipids evoked apoptosis of human pancreatic cancer SOJ-6 cells. Based on the lipid composition of efficient exosomes we designed Synthetic Exosome-Like Nanoparticles (SELN) in which the ratio ordered lipids versus disordered lipids was equal to 6.0 (SELN6.0). These SELN decreased SOJ-6 cells survival by inhibiting the Notch-1 pathway. However MiaPaCa-2 cells were resistant to exosomes (Ristorcelli et al., 2008) and to SELN6.0 (Beloribi et al.,2012). In this paper we aimed at deciphering the reason(s) of this resistance. We observed, in presence of SELN6.0, that the expression of the Notch IntraCytoplasmic Domain (NICD) decreases in MiaPaCa-2 cells but neither Hes-1, the nuclear target of NICD, nor the ratio Bax/Bcl-2 were affected. We further showed that in MiaPaCa-2 cells SELN6.0 induced the activation of NF-kB, which promotes the expression and the secretion of SDF-1α. This chemokine interacts with its receptor CXCR4 on MiaPaCa-2 cells and activates the Akt survival pathway protecting cells from death. This activation process promoted by exosomal lipids could have implications in tumor progression and drug resistance.


  • Open Access

    Exosomal Lipids Impact Notch Signaling and Induce Death of Human Pancreatic Tumoral SOJ-6 Cells

    by Sadia Beloribi, Elodie Ristorcelli, Gilles Breuzard, Françoise Silvy, Justine Bertrand-Michel, Evelyne Beraud, Alain Verine, Dominique Lombardo

    Exosomes are of increasing interest as alternative mode of cell-to-cell communication. We previously reported that exosomes secreted by human SOJ-6 pancreatic tumor cells induce (glyco)protein ligand-independent cell death and inhibit Notch-1 pathway, this latter being particularly active during carcinogenesis and in cancer stem cells. Therefore, we asked whether exosomal lipids were key-elements for cell death and hypothesized that cholesterol-rich membrane microdomains were privileged sites of exosome interactions with tumor cells. To address these questions and based on the lipid composition of exosomes from SOJ-6 cells (Ristorcelli et al. (2008) FASEB J. 22; 3358–3369) enriched in cholesterol and sphingomyelin (lipids forming liquid-ordered phase, Lo) and depleted in phospholipids (lipids forming liquid-disordered phase, Ld), we designed Synthetic Exosome-Like Nanoparticles (SELN) with ratios Lo/Ld from 3.0 to 6.0 framing that of SOJ-6 cell exosomes. SELN decreased tumor cell survival, the higher the Lo/Ld ratio, the lower the cell survival. This decreased survival was due to activation of cell death with inhibition of Notch pathway. FRET analyses indicated fusions/exchanges of SELN with cell membranes. Fluorescent SELN co-localized with the ganglioside GM1 then with Rab5A, markers of lipid microdomains and of early endosomes, respectively. These interactions occurred at lipid microdomains of plasma and/or endosome membranes where the Notch-1 pathway matures. We thus demonstrated a major role for lipids in interactions between SELN and tumor cells, and in the ensued cell death. To our knowledge this is the first report on such effects of lipidic nanoparticles on tumor cell behavior. This may have implications in tumor progression.


  • Decrease of human pancreatic cancer cell tumorigenicity by ?1,3galactosyltransferase gene transfer

    by Muriel Aubert, Christian Crotte, Jean-Paul Bernard, Dominique Lombardo, Marie-Odile Sadoulet, Eric Mas

    The enzyme α1,3galactosyltransferase synthesizes the αGal epitope, a carbohydrate structure (Galα1,3Galβ1,4GlcNAc‐R), on glycoconjugates in lower mammals. The enzyme is absent in humans but large amounts of natural antibodies that recognize αGal epitopes are present in human serum. It is likely that these antibodies contribute to the host defense and participate in the hyperacute rejection of xenograft. Previous studies indicated that the glycosyltransferase gene transfer into tumoral cells can modify the structure of glycoconjugates at the cell surface and, as a consequence, modulates the metastatic and tumorigenic behaviors of these cells. The aim of our study was to determine whether the expression of αGal epitope can modify the tumorigenicity of human pancreatic cancer cells. The expression of αGal epitopes in the human pancreatic cancer cell lines BxPC‐3 and Panc‐1 was obtained by selecting stable cell clones transfected with murine α1,3galactosyltransferase gene. The expression of the enzyme activity in BxPC‐3 and Panc‐1 cells resulted in the formation at the cell surface of αGal epitopes that are recognized by human anti‐αGal antibodies. αGal epitope expression at the surface of pancreatic cancer cells was associated with the fixation of complement 1q to human anti‐αGal antibodies. The αGal epitope expression also resulted in a delay in the tumoral development of BxPC‐3 and Panc‐1 cells in vivo after xenograft transplantation of nude mice. In addition to the impairment of the metastatic potential of murine tumor cell lines and the activation of immune response, our study provides evidence that the cell surface expression of αGal epitopes also modulates the tumorigenic behavior of human pancreatic cancer cells.